Lancet Oncol. 2024 Jun 14:S1470-2045(24)00341-3. doi: 10.1016/S1470-2045(24)00341-3. Online ahead of print.
NO ABSTRACT
PMID:38889736 | DOI:10.1016/S1470-2045(24)00341-3
Recent Content
- Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
- Video: Pharmacists Take Center Stage in Delivering Linvoseltamab, Advancing Myeloma Care
- SAR446523 Granted Orphan Drug Designation for Patients With Relapsed, Refractory Multiple Myeloma
- FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma
- Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT
- Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
- Expert: Linvoseltamab’s Simplified Dosing Expands Access, Enhances Tolerability in Multiple Myeloma
- Patient Perspective: Navigating Multiple Myeloma Treatment
- LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy
- High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease